Prequalified vaccines
Displaying 101 - 150 of 262
Download list as CSV file
| Date of Prequalification | WHO Product ID | Vaccine type | Commercial Name Sort descending | Pharmaceutical Form | Presentation | No. of doses | Manufacturer | Responsible NRA |
|---|---|---|---|---|---|---|---|---|
| FVP-P-292 | Influenza vaccine trivalent (split virion, inactivated) | Influenza Vaccine (Split virion inactivated) | Liquid: Ready to use | Vial | 1 | Hualan Biological Bacterin Inc. | National Medical Products Administration (NMPA) | |
| FVP-P-455 | Influenza vaccine trivalent (split virion, inactivated) | Influeza Vaccine (Split Virion), Inactivated | Liquid: Ready to use | Vial | 1 | 0013X00003VGpVIQA1 | National Medical Products Administration (NMPA) | |
| FVP-P-231 | Poliomyelitis vaccine (inactivated) | IPV Vaccine SSI | Liquid: Ready to use | Vial | 1 | AJ Vaccines A/S | Danish Medicines Agency | |
| FVP-P-272 | Japanese encephalitis vaccine (live, attenuated) for human use | Japanese Encephalitis Vaccine Live (SA14-14-2) | Lyophilised active component to be reconstituted with excipient diluent before use | Two vial set (active + excipient) | 5 | Chengdu Institute of Biological Products Co. Ltd | National Medical Products Administration (NMPA) | |
| FVP-P-271 | Japanese encephalitis vaccine (live, attenuated) for human use | Japanese Encephalitis Vaccine Live (SA14-14-2) | Lyophilised active component to be reconstituted with excipient diluent before use | Two vial set (active + excipient) | 1 | Chengdu Institute of Biological Products Co. Ltd | National Medical Products Administration (NMPA) | |
| FVP-P-360 | Japanese encephalitis vaccine (inactivated) for human use | JEEV® (3µg) | Liquid: Ready to use | Vial | 5 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-321 | Japanese encephalitis vaccine (inactivated) for human use | JEEV® (3µg) | Liquid: Ready to use | Vial | 1 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-263 | Japanese encephalitis vaccine (inactivated) for human use | JEEV® (6µg) | Liquid: Ready to use | Vial | 1 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-359 | Japanese encephalitis vaccine (inactivated) for human use | JEEV® (6µg) | Liquid: Ready to use | Vial | 5 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-375 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine (Live) (Attenuated Freeze Dried) | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 10 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-374 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine (Live) (Attenuated Freeze Dried) | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 5 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-342 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine (Live) (Attenuated Freeze Dried) | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 1 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-139 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 5 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-140 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 10 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-137 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 1 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-138 | Measles, rubella combined vaccine (live, attenuated) | Measles and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 2 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-142 | Measles, mumps, rubella combined vaccine (live, attenuated) | Measles Mumps and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 2 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-143 | Measles, mumps, rubella combined vaccine (live, attenuated) | Measles Mumps and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 5 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-141 | Measles, mumps, rubella combined vaccine (live, attenuated) | Measles Mumps and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 1 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-144 | Measles, mumps, rubella combined vaccine (live, attenuated) | Measles Mumps and Rubella Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 10 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-17 | Measles vaccine (live, attenuated) | Measles vaccine | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 10 | PT Bio Farma (Persero) | National Agency of Drug and Food Control Indonesia (NADFCI) | |
| FVP-P-252 | Measles vaccine (live, attenuated) | Measles vaccine | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 20 | PT Bio Farma (Persero) | National Agency of Drug and Food Control Indonesia (NADFCI) | |
| FVP-P-145 | Measles vaccine (live, attenuated) | Measles Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 1 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-147 | Measles vaccine (live, attenuated) | Measles Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 5 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-148 | Measles vaccine (live, attenuated) | Measles Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 10 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-146 | Measles vaccine (live, attenuated) | Measles Vaccine Live Attenuated | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 2 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-269 | Meningococcal conjugate vaccine tetravalent ( type A,C, Y, W-135) | Menactra | Liquid: Ready to use | Vial | 1 | Sanofi Pasteur Inc. | CBER/FDA | |
| FVP-P-427 | Meningococcal polysacharide conjugate vaccine (type A,C,Y,W,X) | MenFive | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 1 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-451 | Meningococcal polysacharide conjugate vaccine (type A,C,Y,W,X) | MenFive | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 5 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-286 | Group A meningococcal conjugate vaccine | Meningococcal A Conjugate 5 micrograms MenAfriVac 5µg | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 10 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-196 | Group A meningococcal conjugate vaccine | Meningococcal A Conjugate MenAfriVac | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 10 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-417 | Meningococcal conjugate vaccine tetravalent ( type A,C, Y, W-135) | MenQuadfi | Liquid: Ready to use | Vial | 1 | Sanofi Pasteur Inc. | European Medicines Agency | |
| FVP-P-267 | Meningococcal conjugate vaccine tetravalent ( type A,C, Y, W-135) | Menveo | Lyophilised active component to be reconstituted with liquid active component before use | Two vial set (active + active) | 1 | GlaxoSmithKline Vaccines S.r.l. | European Medicines Agency | |
| FVP-P-189 | Poliomyelitis vaccines (monovalent oral, live, attenuated, type 1) | Monovalent Oral Poliomyelitis Vaccine Type 1 (mOPV1) | Liquid: Ready to use | Vial | 20 | PT Bio Farma (Persero) | National Agency of Drug and Food Control Indonesia (NADFCI) | |
| FVP-P-358 | Poliomyelitis vaccines (monovalent oral, live, attenuated, type 2) | Monovalent Oral Poliomyelitis Vaccine Type 2 | Liquid: Ready to use | Vial | 20 | PT Bio Farma (Persero) | National Agency of Drug and Food Control Indonesia (NADFCI) | |
| FVP-P-186 | Poliomyelitis vaccines (monovalent oral, live, attenuated, type 1) | Monovalent type 1 Oral Poliomyelitis vaccine IP (mOPV1) | Liquid: Ready to use | Vial | 20 | Haffkine Bio Pharmaceutical Corporation Ltd | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-424 | Recombinant malaria vaccine | Mosquirix | Liquid: Active component to be mixed with second component before use | Two vial set (active + active) | 2 | GlaxoSmithKline Biologicals SA | European Medicines Agency | |
| FVP-P-409 | Ebola vaccine (recombinant) | Mvabea | Liquid: Ready to use | Vial | 1 | Janssen Vaccines Branch of Cilag GmbH International (Janssen-Cilag) | European Medicines Agency | |
| FVP-P-258 | Human pandemic influenza vaccine | NASOVAC Influenza Vaccine Live Attenuated (Human) Freeze-Dried | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 5 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-257 | Human pandemic influenza vaccine | NASOVAC Influenza Vaccine Live Attenuated (Human) Freeze-Dried | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 1 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-284 | Influenza vaccine trivalent (live, attenuated) | Nasovac-S Influenza Vaccine Live Attenuated (Human) | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 1 | Serum Institute of India Pvt. Ltd. | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-301 | Meningococcal conjugate vaccine tetravalent ( type A,C, Y, W-135) | Nimenrix | Lyophilised active component to be reconstituted with excipient diluent before use | Vial + Ampoule | 1 | Pfizer Europe MA EEIG (Pfizer) | European Medicines Agency | |
| FVP-P-245 | Diphtheria and tetanus vaccine (adsorbed, reduced diphtheria antigen content) | none | Liquid: Ready to use | Vial | 10 | PT Bio Farma (Persero) | National Agency of Drug and Food Control Indonesia (NADFCI) | |
| FVP-P-175 | Yellow fever vaccine (live attenuated) | none | Lyophilised active component to be reconstituted with excipient diluent before use | Ampoule | 2 | Federal State Budgetary Scientific Institution «Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products» Russian Academy of Sciences | Federal Service on Surveillance in Healthcare (ROSZDRAVNADZOR) of the Russian Federation | |
| FVP-P-176 | Yellow fever vaccine (live attenuated) | none | Lyophilised active component to be reconstituted with excipient diluent before use | Ampoule | 5 | Federal State Budgetary Scientific Institution «Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products» Russian Academy of Sciences | Federal Service on Surveillance in Healthcare (ROSZDRAVNADZOR) of the Russian Federation | |
| FVP-P-177 | Yellow fever vaccine (live attenuated) | none | Lyophilised active component to be reconstituted with excipient diluent before use | Ampoule | 10 | Federal State Budgetary Scientific Institution «Chumakov Federal Scientific Center for Research & Development of Immune-And Biological Products» Russian Academy of Sciences | Federal Service on Surveillance in Healthcare (ROSZDRAVNADZOR) of the Russian Federation | |
| FVP-P-403 | Varicella | None | Lyophilised active component to be reconstituted with excipient diluent before use | Vial | 1 | Sinovac Vaccine Technology Co. Ltd. (Sinovac (Dalian) | National Medical Products Administration (NMPA) | |
| FVP-P-399 | Diphtheria and tetanus vaccine (adsorbed, reduced diphtheria antigen content) | None used on labelling for supply through UN agencies. Also marketed with labelled commercial name BE Td | Liquid: Ready to use | Vial | 20 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-280 | Diphtheria and tetanus vaccine (adsorbed, reduced diphtheria antigen content) | None used on labelling for supply through UN agencies. Also marketed with labelled commercial name BE Td | Liquid: Ready to use | Vial | 10 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) | |
| FVP-P-279 | Diphtheria and tetanus vaccine (adsorbed, reduced diphtheria antigen content) | None used on labelling for supply through UN agencies. Also marketed with labelled commercial name BE Td | Liquid: Ready to use | Vial | 1 | Biological E. Limited | Central Drugs Standard Control Organization (CDSCO) |
.